Begin main content

glecaprevir pibrentasvir

Last Updated: February 8, 2018
Result type: Reports
Project Number: SR0523-000
Product Line: Common Drug Review

Generic Name: glecaprevir pibrentasvir

Brand Name: Maviret

Manufacturer: AbbVie Corporation

Indications: Hepatitis C, chronic

Submission Type: New

Project Status: Complete

Biosimilar: No

Date Recommendation Issued: January 23, 2018

Recommendation Type: Reimburse with clinical criteria and/or conditions

Fee Schedule1: Schedule A

Key Milestones2

Call for patient input posted3May 11, 2017
Patient group input closed3June 30, 2017

- Patient input submission received

Patient input summary sent for review to patient input groupsJuly 19, 2017
Patient group comments on input summary closedJuly 26, 2017

- Patient input summary feedback received

Submission receivedJune 09, 2017
Submission accepted for reviewJune 23, 2017
Review initiatedJune 26, 2017
Draft CDR review report(s) sent to applicantSeptember 28, 2017
Comments from applicant on draft CDR review report(s) receivedOctober 10, 2017
Redaction requests from applicant on draft CDR review report(s) receivedOctober 17, 2017
CDR review team's comments on draft CDR review report(s) sent to applicantDecember 01, 2017
Canadian Drug Expert Committee (CDEC) meetingDecember 13, 2017
CDEC recommendation & redacted CDR review report(s) sent to applicant and drug plansJanuary 02, 2018
Embargo4 period ended and validation of redacted CDR review report(s) receivedJanuary 16, 2018
CDEC Final Recommendation issued to applicant and drug plansJanuary 23, 2018
CDEC Final Recommendation posted5January 25, 2018
Final CDR review report(s) and patient input posted5February 08, 2018
  1. Refer to Appendix 1 of the Procedure for the CADTH Common Drug Review for details regarding CDR application fee schedules.
  2. Please refer to the Procedure for the CADTH Common Drug Review for complete details regarding the CDR process and targeted time frames for key milestones.
  3. The call for patient group input is posted 20 business days in advance of the applicant's anticipated date of filing the CDR application. Patient groups have a total of 35 business days for preparing and submitting patient input.
  4. The embargoed CDEC recommendation is held in confidence by all stakeholders and not acted upon until after CADTH has issued the notice of CDEC Final Recommendation.The applicant may make a request for reconsideration or resubmission based on reduced price during the embargo period, and the drug plans may make a request for clarification, as applicable (see section 8 of the Procedure for the CADTH Common Drug Review).
  5. The timing for posting the CDEC Final Recommendation and CDR review report(s) depends on several factors including the need for consultation with the applicant regarding redaction issues.
  6. The time frame required to address a request for clarification at the drug plans' request or request for reconsideration at the applicant's request depends on the amount of work required to address the request and the available dates for CDEC meetings.


hepatitis, hepatitis c, chronic, maviret; glecaprevir/pibrentasvir; mavyret